Chinese Medicine Shensongyangxin Is Effective for Patients with Bradycardia: Results of a Randomized, Double-Blind, Placebo-Controlled Multicenter Trial

Table 2

Heart rate in the trial group and the control group at baseline and 4 weeks.

HR variables	Trial group	Control group	𝑃 value
AHR (bpm)
Baseline	53.38±5.16	53.83±4.17	0.482
4 weeks	60.50±8.70^∗	56.50±5.99^∗	0.000
FHR (bpm)
Baseline	95.50±24.94	95.31±20.64	0.952
4 weeks	105.54±24.97^#	98.93±18.85	0.029
LHR (bpm)
Baseline	33.50±3.62	33.98±3.91	0.350
4 weeks	40.74±7.67^#	38.08±5.85^#	0.005

HR: heart rate; AHR: average heart rate; FHR: fastest heart rate (bpm); LHR: lowest heart rate.
At baseline, there are 115 patients in the trial group and 104 patients in the control group. At the end of 4 weeks, 1 patient in the trial group and 4 patients in the control group refused to repeat 24-hour Holter, so their HR variables are missed.
^∗𝑃<0.05 versus pretreatment in the same group.
^#𝑃<0.01 versus pretreatment in the same group.